Yin Nuo Pharmaceutical-B (02591): Two manufacturing sites for Isupegadex injection solution have obtained PIC/S GMP certification.

Zhitong Finance APP news, Yin Nuo Pharmaceutical-B (02591) announced that on July 27, 2026, two commissioned production sites for the isupreptide injection project located in China (both owned and operated by independent third parties) have passed the compliance inspection according to the Good Manufacturing Practice (GMP) standards conducted by the Brazilian National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Cooperation Scheme (PIC/S), and ANVISA has issued the relevant GMP certificates.